| Year |
Citation |
Score |
| 2020 |
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. PMID 32127639 DOI: 10.1038/S41375-020-0776-2 |
0.372 |
|
| 2019 |
Akkouh IA, Skrede S, Holmgren A, Ersland KM, Hansson L, Bahrami S, Andreassen OA, Steen VM, Djurovic S, Hughes T. Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31652432 DOI: 10.1038/S41386-019-0556-8 |
0.307 |
|
| 2018 |
Hiwase D, Tan P, D'Rozario J, Taper J, Powell A, Irving I, Wright M, Branford S, Yeung DT, Anderson L, Gervasio O, Levetan C, Roberts W, Solterbeck A, Traficante R, ... Hughes T, et al. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leukemia Research. 67: 109-115. PMID 29494928 DOI: 10.1016/J.Leukres.2018.02.013 |
0.352 |
|
| 2017 |
Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. PMID 28387926 DOI: 10.1002/Cncr.30558 |
0.332 |
|
| 2017 |
Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, et al. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 175-184. PMID 28056193 DOI: 10.1200/Jco.2016.67.0893 |
0.347 |
|
| 2017 |
Banjar H, Ranasinghe D, Brown F, Adelson D, Kroger T, Leclercq T, White D, Hughes T, Chaudhri N. Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia. Plos One. 12: e0168947. PMID 28045960 DOI: 10.1371/Journal.Pone.0168947 |
0.352 |
|
| 2017 |
Radich J, Mahon F, Hochhaus A, Hughes T, Ailawadhi S, Lipton J, Gopalakrishna P, Fellague-Chebra R, Deng W, Acharya S, Saglio G. ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Clinical Lymphoma Myeloma and Leukemia. 17: S314-S315. DOI: 10.1016/J.Clml.2017.07.115 |
0.338 |
|
| 2016 |
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, ... ... Hughes T, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 27083332 DOI: 10.1016/S1470-2045(16)00080-2 |
0.373 |
|
| 2016 |
Mahon F, Hochhaus A, Hughes T, Ailawadhi S, Lipton J, Wolff J, Saglio G. Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop Clinical Lymphoma Myeloma and Leukemia. 16: S64-S65. DOI: 10.1016/J.Clml.2016.07.094 |
0.344 |
|
| 2015 |
Watkins DB, Hughes TP, White DL. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. PMID 26122430 DOI: 10.1038/Leu.2015.170 |
0.34 |
|
| 2015 |
Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. PMID 26118315 DOI: 10.1038/Leu.2015.168 |
0.368 |
|
| 2014 |
Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 99: 1701-9. PMID 25216683 DOI: 10.3324/Haematol.2013.085977 |
0.388 |
|
| 2014 |
Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, et al. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4: e238. PMID 25127392 DOI: 10.1038/Bcj.2014.60 |
0.381 |
|
| 2013 |
Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013: 168-75. PMID 24319178 DOI: 10.1182/Asheducation-2013.1.168 |
0.376 |
|
| 2013 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Hughes T, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 369: 1783-96. PMID 24180494 DOI: 10.1056/Nejmoa1306494 |
0.4 |
|
| 2013 |
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology. 163: 674-6. PMID 24032404 DOI: 10.1111/Bjh.12532 |
0.312 |
|
| 2013 |
Ross DM, O'Hely M, Bartley PA, Dang P, Score J, Goyne JM, Sobrinho-Simoes M, Cross NC, Melo JV, Speed TP, Hughes TP, Morley AA. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia. 27: 2105-7. PMID 23588714 DOI: 10.1038/Leu.2013.116 |
0.32 |
|
| 2013 |
White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clinical Chemistry. 59: 938-48. PMID 23471097 DOI: 10.1373/Clinchem.2012.196477 |
0.32 |
|
| 2013 |
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 27: 107-12. PMID 22763385 DOI: 10.1038/Leu.2012.181 |
0.393 |
|
| 2012 |
Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. Journal of the National Comprehensive Cancer Network : Jnccn. 10: S1-S13. PMID 23055247 DOI: 10.6004/Jnccn.2012.0184 |
0.371 |
|
| 2012 |
Mauro MJ, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, ... ... Hughes T, et al. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial Blood. 120: 3747-3747. DOI: 10.1182/Blood.V120.21.3747.3747 |
0.331 |
|
| 2012 |
Branford S, Ross D, Prime J, Field C, Altamura H, Yeoman A, Georgievski J, Phillis S, Jamison BA, Sullivan B, Yeung DT, Hughes T. Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML Blood. 120: 165-165. DOI: 10.1182/Blood.V120.21.165.165 |
0.38 |
|
| 2012 |
Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Hughes T, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial Blood. 120: 163-163. DOI: 10.1182/Blood.V120.21.163.163 |
0.354 |
|
| 2011 |
Engler JR, Hughes TP, White DL. OCT-1 as a determinant of response to antileukemic treatment. Clinical Pharmacology and Therapeutics. 89: 608-11. PMID 21346750 DOI: 10.1038/Clpt.2011.12 |
0.389 |
|
| 2011 |
Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 524-31. PMID 21220597 DOI: 10.1200/Jco.2010.31.3619 |
0.342 |
|
| 2010 |
White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, ... ... Hughes T, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 116: e111-7. PMID 20720184 DOI: 10.1182/Blood-2010-06-291641 |
0.304 |
|
| 2010 |
Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. International Journal of Laboratory Hematology. 32: e222-8. PMID 20491997 DOI: 10.1111/J.1751-553X.2010.01236.X |
0.318 |
|
| 2010 |
Osborn M, Hughes T. Managing imatinib resistance in chronic myeloid leukaemia Current Opinion in Hematology. 17: 97-103. PMID 20061946 DOI: 10.1097/Moh.0B013E3283366Bcb |
0.386 |
|
| 2010 |
Parker WT, Ho M, Lawrence RM, Irwin DL, Scott HS, Hughes T, Branford S. Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance Blood. 116: 891-891. DOI: 10.1182/Blood.V116.21.891.891 |
0.316 |
|
| 2010 |
White DL, Saunders V, Frede A, GrootObbink K, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study Blood. 116: 356-356. DOI: 10.1182/Blood.V116.21.356.356 |
0.382 |
|
| 2010 |
Kim D, Kim D, Kim S, Goh H, Pane F, Hughes T, Radich JP, Lin P, Saglio G, Branford S, Martinelli G, Soverini S, Hochhaus A. Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment. Blood. 116: 3441-3441. DOI: 10.1182/Blood.V116.21.3441.3441 |
0.379 |
|
| 2010 |
Tang C, Schafranek L, Watkins D, Parker WT, Prime J, White DL, Hughes T. Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression. Blood. 116: 3383-3383. DOI: 10.1182/Blood.V116.21.3383.3383 |
0.305 |
|
| 2010 |
White DL, Saunders V, Andrew M, Rofe A, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. Imatinib PK: Observations From the TIDEL II Study Blood. 116: 2288-2288. DOI: 10.1182/Blood.V116.21.2288.2288 |
0.314 |
|
| 2010 |
Morley AA, Bartley P, Ross D, Latham S, Budgen B, Branford S, Hughes T. Towards DNA-Based Monitoring of Therapy In Chronic Myeloid Leukemia Blood. 116: 2284-2284. DOI: 10.1182/Blood.V116.21.2284.2284 |
0.342 |
|
| 2010 |
Yeung DT, Osborn M, White DL, Branford S, Haswell L, Slader C, Issa S, Hiwase DK, Hertzberg MS, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Forsyth CJ, Ross DM, ... ... Hughes T, et al. Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial Blood. 116: 209-209. DOI: 10.1182/Blood.V116.21.209.209 |
0.336 |
|
| 2010 |
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes T, Larson RA. Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) Leukemia. 24. DOI: 10.1038/Leu.2010.71 |
0.346 |
|
| 2009 |
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6041-51. PMID 19884523 DOI: 10.1200/Jco.2009.25.0779 |
0.307 |
|
| 2009 |
Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4204-10. PMID 19652056 DOI: 10.1200/Jco.2009.21.8230 |
0.396 |
|
| 2009 |
Hughes T, Hochhaus A. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. Seminars in Hematology. 46: S11-5. PMID 19621544 DOI: 10.1053/J.Seminhematol.2009.01.008 |
0.333 |
|
| 2009 |
Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 115: 4136-47. PMID 19536906 DOI: 10.1002/Cncr.24504 |
0.331 |
|
| 2009 |
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. International Journal of Hematology. 89: 679-688. PMID 19449194 DOI: 10.1007/S12185-009-0327-0 |
0.371 |
|
| 2009 |
Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes T, Holyoake TL. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia. 23: 1199-1201. PMID 19262595 DOI: 10.1038/Leu.2009.43 |
0.302 |
|
| 2009 |
White DL, Saunders VA, Frede A, Dang P, Zrim S, Osborn MP, Manley P, Hughes T. The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. Blood. 114: 507-507. DOI: 10.1182/Blood.V114.22.507.507 |
0.385 |
|
| 2009 |
Branford S, Hochhaus A, Mueller M, Bahceci E, Ploughman L, Mukhopadhyay J, Hughes T. Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure. Blood. 114: 3282-3282. DOI: 10.1182/Blood.V114.22.3282.3282 |
0.332 |
|
| 2009 |
Hiwase DK, White DL, Powell JA, Saunders VA, Zrim S, Frede A, Guthridge M, D'Andrea R, To LB, Melo JV, Kumar S, Hughes T. Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. Blood. 114: 3250-3250. DOI: 10.1182/Blood.V114.22.3250.3250 |
0.313 |
|
| 2009 |
Esposito N, Quintarelli C, Colavita I, Izzo B, Peluso AL, Ruoppolo M, Vecchio LD, Russo D, Branford S, Iacobucci I, Thornquist M, Barnett M, Melo J, Saglio G, Radich J, ... ... Hughes T, et al. Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. Blood. 114: 2212-2212. DOI: 10.1182/Blood.V114.22.2212.2212 |
0.422 |
|
| 2008 |
Hughes T, Liberles DA. Whole-genome duplications in the ancestral vertebrate are detectable in the distribution of gene family sizes of tetrapod species. Journal of Molecular Evolution. 67: 343-57. PMID 18815825 DOI: 10.1007/S00239-008-9145-X |
0.562 |
|
| 2008 |
Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, ... Hughes T, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 112: 3330-8. PMID 18684859 DOI: 10.1182/Blood-2008-04-150680 |
0.321 |
|
| 2008 |
Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, ... Hughes T, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3204-12. PMID 18541900 DOI: 10.1200/Jco.2007.14.9260 |
0.331 |
|
| 2008 |
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, ... Hughes T, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 22: 1200-6. PMID 18401416 DOI: 10.1038/Leu.2008.84 |
0.39 |
|
| 2008 |
Hughes T, Liberles DA. The power-law distribution of gene family size is driven by the pseudogenisation rate's heterogeneity between gene families. Gene. 414: 85-94. PMID 18378100 DOI: 10.1016/J.Gene.2008.02.014 |
0.543 |
|
| 2008 |
Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia Seminars in Oncology. 35. PMID 18346528 DOI: 10.1053/J.Seminoncol.2007.12.002 |
0.412 |
|
| 2008 |
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, ... ... Hughes T, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 111: 1834-9. PMID 18048643 DOI: 10.1182/Blood-2007-04-083196 |
0.371 |
|
| 2008 |
Saglio G, Radich J, Kim D, Martinelli G, Branford S, Mueller M, Soverini S, Shou Y, Hochhaus A, Hughes T. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060 Journal of Clinical Oncology. 26: 7060-7060. DOI: 10.1200/Jco.2008.26.15_Suppl.7060 |
0.371 |
|
| 2008 |
Hochhaus A, Mueller M, Cortes JE, Kim D, Matlob Y, Ploughman L, Hughes T. Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure Journal of Clinical Oncology. 26: 7014-7014. DOI: 10.1200/Jco.2008.26.15_Suppl.7014 |
0.323 |
|
| 2008 |
Branford S, Lawrence R, Fletcher L, Field C, Rudzki Z, Hughes T. The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening Blood. 112: 331-331. DOI: 10.1182/Blood.V112.11.331.331 |
0.331 |
|
| 2008 |
White DL, Saunders VA, Dang P, Frede A, Eadie L, Soverini S, Quarantelli F, Lin P, Thornquist M, Kim D, Pane F, Martinelli G, Radich J, Kalebic T, Saglio G, ... Hughes T, et al. CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study Blood. 112: 3187-3187. DOI: 10.1182/Blood.V112.11.3187.3187 |
0.345 |
|
| 2008 |
Esposito N, Colavita I, Quarantelli F, Izzo B, Luciano L, Vecchio LD, Hughes T, Radich J, Russo D, Soverini S, Iacobucci I, Martinelli G, Saglio G, Melo J, Ruoppolo M, et al. A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment Blood. 112: 3186-3186. DOI: 10.1182/Blood.V112.11.3186.3186 |
0.356 |
|
| 2008 |
Morley AA, Bartley P, Ross DM, Latham S, Martin-Harris H, Budgen B, Wilczek V, Branford S, Hughes T. DNA-Based Monitoring of Minimal Residual Disease(MRD) in Chronic Myeloid Leukemia(CML). Blood. 112: 1111-1111. DOI: 10.1182/Blood.V112.11.1111.1111 |
0.307 |
|
| 2008 |
Esposito N, Quarantelli F, Luciano L, Izzo B, Peluso AL, Picardi M, Branford S, White DL, Hughes T, Radich J, Soverini S, Iacobucci I, Saglio G, Kalebic T, Thornquist M, et al. The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. Blood. 112: 1106-1106. DOI: 10.1182/Blood.V112.11.1106.1106 |
0.394 |
|
| 2008 |
Ross DDM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills AK, Filshie R, Columbus R, Reynolds J, Seymour JF, Branford S, Hughes T. The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. Blood. 112: 1102-1102. DOI: 10.1182/Blood.V112.11.1102.1102 |
0.392 |
|
| 2007 |
Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research. 13: 7080-7085. PMID 18056186 DOI: 10.1158/1078-0432.Ccr-07-0844 |
0.391 |
|
| 2007 |
Hughes T, Liberles DA. The pattern of evolution of smaller-scale gene duplicates in mammalian genomes is more consistent with neo- than subfunctionalisation. Journal of Molecular Evolution. 65: 574-88. PMID 17957399 DOI: 10.1007/S00239-007-9041-9 |
0.561 |
|
| 2007 |
White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4445-51. PMID 17906206 DOI: 10.1200/Jco.2006.09.9499 |
0.375 |
|
| 2007 |
White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 110: 4064-72. PMID 17761829 DOI: 10.1182/Blood-2007-06-093617 |
0.34 |
|
| 2007 |
Branford S, Hughes T, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near‐complete cytogenetic response to interferon‐α Cancer. 110: 801-808. PMID 17607681 DOI: 10.1002/Cncr.22842 |
0.362 |
|
| 2007 |
Hughes T, Ekman D, Ardawatia H, Elofsson A, Liberles DA. Evaluating dosage compensation as a cause of duplicate gene retention in Paramecium tetraurelia. Genome Biology. 8: 213. PMID 17521457 DOI: 10.1186/Gb-2007-8-5-213 |
0.548 |
|
| 2007 |
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 109: 5143-50. PMID 17317857 DOI: 10.1182/Blood-2006-11-056028 |
0.36 |
|
| 2007 |
Mueller MC, Branford S, Radich J, Kim DW, Martinelli G, Saglio G, Hughes T, Shou Y, Weitzman A, Baccarani M, Hochhaus A. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure Journal of Clinical Oncology. 25: 7024-7024. DOI: 10.1200/Jco.2007.25.18_Suppl.7024 |
0.353 |
|
| 2007 |
Hochhaus A, Branford S, Radich J, Mueller MC, Shah N, Erben P, Ernst T, Acevedo M, Nicaise C, Hughes T. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR- ABL mutations Journal of Clinical Oncology. 25: 7023-7023. DOI: 10.1200/Jco.2007.25.18_Suppl.7023 |
0.348 |
|
| 2007 |
Stone RM, Kantarjian HM, Baccarani M, Lipton JH, Hughes T, Ezzeddine R, Bleickardt E, Hochhaus A. Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013). Blood. 110: 734-734. DOI: 10.1182/Blood.V110.11.734.734 |
0.402 |
|
| 2007 |
Hughes T, Saglio G, Martinelli G, Kim D, Soverini S, Mueller M, Haque A, Gallagher N, Shou Y, Radich J, Branford S, Hochhaus A. Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types. Blood. 110: 320-320. DOI: 10.1182/Blood.V110.11.320.320 |
0.309 |
|
| 2007 |
Morley A, Bartley P, Martin-Harris H, Latham S, Ross D, Hughes T. DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML). Blood. 110: 2946-2946. DOI: 10.1182/Blood.V110.11.2946.2946 |
0.325 |
|
| 2007 |
Saglio G, Kim D, Hochhaus A, Soverini S, Erben P, Branford S, Haque A, Gallagher N, Shou Y, Hughes T, Martinelli G, Radich J. Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance. Blood. 110: 1940-1940. DOI: 10.1182/Blood.V110.11.1940.1940 |
0.31 |
|
| 2007 |
Heaney N, Drummond M, Kaeda J, Nicolini F, Clark R, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes T, Holyoake TL. A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib. Blood. 110: 1033-1033. DOI: 10.1182/Blood.V110.11.1033.1033 |
0.359 |
|
| 2007 |
Branford S, Fletcher L, Cross NC, Hochhaus A, Mueller MC, Kim D, Radich J, Saglio G, Pane F, Lynch K, Goldman JM, Hughes T. Validation of the International Scale for Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. Blood. 110: 1013-1013. DOI: 10.1182/Blood.V110.11.1013.1013 |
0.3 |
|
| 2007 |
Hughes T, Branford S. Ph+ ALL: resistance seeds sown early Blood. 110: 472-472. DOI: 10.1182/Blood-2007-04-085274 |
0.319 |
|
| 2006 |
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, ... ... Hughes T, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 355: 2408-17. PMID 17151364 DOI: 10.1056/Nejmoa062867 |
0.369 |
|
| 2006 |
Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 211-218. PMID 17124063 DOI: 10.1182/Asheducation-2006.1.211 |
0.399 |
|
| 2006 |
Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J, Hughes T. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 20: 1925-30. PMID 16990771 DOI: 10.1038/Sj.Leu.2404388 |
0.351 |
|
| 2006 |
Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biology of Blood and Marrow Transplantation. 12: 795-807. PMID 16864049 DOI: 10.1016/J.Bbmt.2006.03.012 |
0.363 |
|
| 2006 |
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 108: 1809-20. PMID 16709930 DOI: 10.1182/Blood-2006-02-005686 |
0.368 |
|
| 2006 |
Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods in Molecular Medicine. 125: 93-106. PMID 16502579 DOI: 10.1385/1-59745-017-0:93 |
0.346 |
|
| 2006 |
Branford S, Hughes T. Diagnosis and Monitoring of Chronic Myeloid Leukemia by Qualitative and Quantitative RT-PCR Methods in Molecular Medicine. 125: 69-92. PMID 16502578 DOI: 10.1385/1-59745-017-0:69 |
0.35 |
|
| 2006 |
Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL Leukemia. 20: 664-670. PMID 16482210 DOI: 10.1038/Sj.Leu.2404139 |
0.39 |
|
| 2006 |
Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews. 20: 29-41. PMID 16426942 DOI: 10.1016/J.Blre.2005.01.008 |
0.391 |
|
| 2006 |
Giles FJ, Larson R, Coutre PL, Baccarani M, Tavorath R, Alland L, Kantarjian HM, Hughes T, Ottmann O. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) Journal of Clinical Oncology. 24: 6536-6536. DOI: 10.1200/Jco.2006.24.18_Suppl.6536 |
0.349 |
|
| 2006 |
Hochhaus A, Erben P, Branford S, Radich J, Kim DW, Martinelli G, Saglio G, Mueller MC, Hoffmann J, Palandri F, Soverini S, Hughes T, Shou Y, Weitzman A, Baccarani M. Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure. Blood. 108: 749-749. DOI: 10.1182/Blood.V108.11.749.749 |
0.342 |
|
| 2006 |
White D, Saunders V, Dang P, Venables A, Zrim S, Reynolds J, Quinn S, Zannettino A, Hughes T. Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib. Blood. 108: 738-738. DOI: 10.1182/Blood.V108.11.738.738 |
0.332 |
|
| 2006 |
Branford S, Seymour JF, Grigg A, Arthur C, Lynch K, Hughes T. Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up. Blood. 108: 430-430. DOI: 10.1182/Blood.V108.11.430.430 |
0.393 |
|
| 2006 |
Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP, Gratwohl A, Rafferty T, Resta D, Gattermann N. A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis. Blood. 108: 2703-2703. DOI: 10.1182/Blood.V108.11.2703.2703 |
0.374 |
|
| 2006 |
Seymour JF, Grigg A, Reynolds J, Schwarer AP, Hermann R, Taylor KM, Bradstock KF, Mills AK, Koelmeyer R, Lynch K, Hughes T. Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML. Blood. 108: 2147-2147. DOI: 10.1182/Blood.V108.11.2147.2147 |
0.306 |
|
| 2006 |
White D, Dang P, Venables A, Saunders V, Zrim S, Zannettino A, Diamond P, Quinn S, To LB, Hughes T. ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance. Blood. 108: 2144-2144. DOI: 10.1182/Blood.V108.11.2144.2144 |
0.385 |
|
| 2006 |
Branford S, Hughes T, Stylian S, Schwarer AP, Arthur C, Filshie R, Moreton S, Rodwell R, Guzzo-Pernell N, Taylor D, Larson J, Koelmayer R, Milner A, Lynch K, Taylor KM. Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN). Blood. 108: 2142-2142. DOI: 10.1182/Blood.V108.11.2142.2142 |
0.377 |
|
| 2006 |
Kaeda J, Hochhaus A, Radich J, Branford S, So C, Gathmann I, Wehrle E, Goldman J, Hughes T. Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1st Line IM Patients. Blood. 108: 2139-2139. DOI: 10.1182/Blood.V108.11.2139.2139 |
0.304 |
|
| 2006 |
Shah N, Pasquini R, Rousselot P, Jootar S, Holowiecki J, Countouriotis A, Dejardin D, Hughes T, Druker BJ. Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study. Blood. 108: 167-167. DOI: 10.1182/Blood.V108.11.167.167 |
0.32 |
|
| 2005 |
White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 106: 2520-6. PMID 15956284 DOI: 10.1182/Blood-2005-03-1103 |
0.383 |
|
| 2005 |
Branford S, Hughes T, Nicoll J, Paquette R, Bleickardt E, Sawyers C, Shah N. Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. Blood. 106: 437-437. DOI: 10.1182/Blood.V106.11.437.437 |
0.39 |
|
| 2005 |
Oehler V, Branford S, Pogosova-Agadjanyan E, Shah N, Sawyers C, Mao M, Linsley P, Hughes T, Radich J. Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. Blood. 106: 433-433. DOI: 10.1182/Blood.V106.11.433.433 |
0.384 |
|
| 2005 |
Branford S, Rudzki Z, Lynch K, Hughes T. Pre-Imatinib Factors Can Be Used To Define the Risk of BCR-ABL Mutations for Patients with CML in Chronic Phase and Identify a Minority Who Should Have Regular Mutation Screening. Blood. 106: 1079-1079. DOI: 10.1182/Blood.V106.11.1079.1079 |
0.35 |
|
| 2004 |
Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, et al. Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia Annals of Oncology. 15: 1810-1815. PMID 15550587 DOI: 10.1093/Annonc/Mdh468 |
0.305 |
|
| 2004 |
Faderl S, Hochhaus A, Hughes T. Monitoring of minimal residual disease in chronic myeloid leukemia. Hematology/Oncology Clinics of North America. 18: 657-70, ix-x. PMID 15271398 DOI: 10.1016/J.Hoc.2004.03.010 |
0.338 |
|
| 2004 |
Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematology/Oncology Clinics of North America. 18: 641-56, ix. PMID 15271397 DOI: 10.1016/J.Hoc.2004.03.001 |
0.333 |
|
| 2004 |
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, ... ... Hughes T, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 104: 2926-32. PMID 15256429 DOI: 10.1182/Blood-2004-03-1134 |
0.355 |
|
| 2004 |
Hughes T, Hyun Y, Liberles DA. Visualising very large phylogenetic trees in three dimensional hyperbolic space. Bmc Bioinformatics. 5: 48. PMID 15117420 DOI: 10.1186/1471-2105-5-48 |
0.515 |
|
| 2004 |
Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? British Journal of Cancer. 90: 12-9. PMID 14710199 DOI: 10.1038/Sj.Bjc.6601507 |
0.305 |
|
| 2004 |
Seymour JF, Grigg A, Reynolds J, Matthews J, Schwarer AP, Herrmann R, Taylor KM, Hertzberg MS, Mills A, Guzzo-Pernell N, Copeman M, Lynch K, Hughes T. Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML. Blood. 104: 1020-1020. DOI: 10.1182/Blood.V104.11.1020.1020 |
0.333 |
|
| 2004 |
Paschka P, Branford S, Lorentz C, Hehlmann R, Hughes T, Hochhaus A. Comparison of "Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients. Blood. 104: 1013-1013. DOI: 10.1182/Blood.V104.11.1013.1013 |
0.348 |
|
| 2004 |
Hughes T, Branford S, Reynolds J, Seymour J, Taylor K, Guzzo-Pernell N, Filshie R, Arthur C, Schwarer A, Hertzberg M, Rudzki Z, Copeman M, Lynch K, Grigg A. Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS. Blood. 104: 1001-1001. DOI: 10.1182/Blood.V104.11.1001.1001 |
0.342 |
|
| 2003 |
Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Seminars in Hematology. 40: 62-68. PMID 12783378 DOI: 10.1053/Shem.2003.50044 |
0.399 |
|
| 2003 |
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine. 348: 994-1004. PMID 12637609 DOI: 10.1056/Nejmoa022457 |
0.351 |
|
| 2003 |
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood. 102: 276-283. PMID 12623848 DOI: 10.1182/Blood-2002-09-2896 |
0.352 |
|
| 2001 |
Hui CH, Bardy P, Hughes T, Horvath N, To LB. Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. Clinical and Laboratory Haematology. 23: 135-8. PMID 11488854 DOI: 10.1046/J.1365-2257.2001.00359.X |
0.323 |
|
| 2000 |
Branford S, Rudzki Z, Hughes T. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology. 109: 635-637. PMID 10886215 DOI: 10.1046/J.1365-2141.2000.02042.X |
0.307 |
|
| 1999 |
Branford S, Hughes T, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics British Journal of Haematology. 107: 587-599. PMID 10583264 DOI: 10.1046/J.1365-2141.1999.01749.X |
0.347 |
|
| 1999 |
Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes T, Herrmann R, Gibson J, Arthur C, Matthews J. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. British Journal of Haematology. 107: 409-418. PMID 10583235 DOI: 10.1046/J.1365-2141.1999.01713.X |
0.313 |
|
| 1997 |
Lewis ID, Haylock DN, Moore S, To LB, Hughes TP. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia. Leukemia. 11: 581-7. PMID 9096699 DOI: 10.1038/Sj.Leu.2400604 |
0.308 |
|
| 1993 |
Cross NCP, Feng L, Chase A, Bungey J, Hughes T, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 82: 1929-1936. DOI: 10.1182/Blood.V82.6.1929.Bloodjournal8261929 |
0.358 |
|
| 1990 |
Morgan GJ, Hernandez A, Chan LC, Hughes T, Martiat P, Wiedemann LM. The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. British Journal of Haematology. 76: 33-38. PMID 2223646 DOI: 10.1111/J.1365-2141.1990.Tb07833.X |
0.352 |
|
| 1989 |
Hughes T, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. British Journal of Haematology. 73: 462-467. PMID 2611134 DOI: 10.1111/J.1365-2141.1989.Tb00281.X |
0.354 |
|
| 1989 |
Morgan GJ, Janssen JWG, Guo AP, Wiedemann LM, Hughes T, Gow J, Goldman JM, Bartram CR. Polymerase chain reaction for detection of residual leukaemia. The Lancet. 333: 928-929. PMID 2565420 DOI: 10.1016/S0140-6736(89)92508-7 |
0.326 |
|
| Show low-probability matches. |